Macrocyclic Spiropiperidine Beta-Secretase Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents are inadequate in effectively inhibiting the beta-secretase enzyme, which contributes to the accumulation of amyloid plaques in the brain, a hallmark of Alzheimer's disease, leading to the progression of the disease.
Innovation Solution
Development of macrocyclic spiropiperidine compounds that act as inhibitors of the beta-secretase enzyme, specifically targeting the enzyme to prevent the formation and accumulation of amyloid plaques by cleaving the amyloid precursor protein.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic agents are used to inhibit beta-secretase enzyme, then the treatment approach for Alzheimer's disease is available, but the inhibition effectiveness is insufficient leading to continued amyloid plaque accumulation
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of beta-secretase inhibitors to achieve macrocyclic spiropiperidine compounds with enhanced binding affinity and inhibitory potency. The structural optimization includes adjusting ring size, substituent positions, and molecular conformation to improve enzyme inhibition effectiveness and reduce amyloid plaque accumulation
Solution Approach 2:
The invention utilizes composite molecular structures combining macrocyclic frameworks with spiropiperidine moieties. This composite structural approach creates a synergistic effect where the macrocyclic portion provides binding stability while the spiropiperidine portion enhances enzymatic inhibition, resulting in superior therapeutic efficacy compared to single-structure inhibitors
2Object-generated harmful factors
If beta-secretase enzyme activity is inhibited to prevent amyloid formation, then the production of amyloid plaques is arrested, but the disease progression continues due to inadequate existing therapies
Solution Approach 1:
The patent applies preliminary action by designing inhibitors that prevent the cleavage of amyloid precursor protein before amyloid plaques can form. The macrocyclic spiropiperidine compounds bind to beta-secretase enzyme in advance, blocking its catalytic activity and preventing the formation of harmful amyloid fragments before they accumulate in the brain
Data Source
AI summary
The present invention is directed to compounds of formula (I)which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.